NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free CANF Stock Alerts $2.03 -0.06 (-2.87%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$2.01▼$2.2150-Day Range$1.92▼$2.4052-Week Range$1.81▼$3.33Volume10,915 shsAverage Volume19,232 shsMarket Capitalization$7.19 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get Can-Fite BioPharma alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Can-Fite BioPharma Stock (NYSE:CANF)Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANF Stock News HeadlinesApril 30, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.comApril 25, 2024 | businesswire.comLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 22, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.comApril 15, 2024 | businesswire.comCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHApril 3, 2024 | businesswire.comCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsMarch 28, 2024 | finanznachrichten.deCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical UpdateMarch 11, 2024 | businesswire.comNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 1, 2024 | investing.comCan-Fite secures Canadian patent for liver disease drugFebruary 28, 2024 | businesswire.comCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaFebruary 24, 2024 | wsj.comHistorical PricesFebruary 22, 2024 | finance.yahoo.comCan-Fite BioPharma Ltd. (CANF)February 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical ProspectsJanuary 30, 2024 | investing.comCan Fite Biopharma Ltd (CANF)January 30, 2024 | investing.comCan Fite Biopharma Ltd ADR (CANF)January 30, 2024 | finance.yahoo.comCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationJanuary 29, 2024 | finance.yahoo.comCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyDecember 20, 2023 | finance.yahoo.comThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesDecember 18, 2023 | markets.businessinsider.comCan-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick FactsDecember 18, 2023 | finance.yahoo.comCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanDecember 4, 2023 | finance.yahoo.comCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentNovember 30, 2023 | finance.yahoo.comCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateNovember 21, 2023 | msn.comWhy Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?November 21, 2023 | finance.yahoo.comCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsNovember 21, 2023 | finance.yahoo.comCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonNovember 1, 2023 | finance.yahoo.comCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on TrackSee More Headlines Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+628.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,630,000.00 Net Margins-1,027.46% Pretax Margin-1,027.46% Return on Equity-113.75% Return on Assets-69.91% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.90 Sales & Book Value Annual Sales$740,000.00 Price / Sales9.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.17Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$7.29 million OptionableNot Optionable Beta1.58 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Pnina Fishman Ph.D. (Age 76)Founder, Chief Scientific Officer & Executive Chairperson Comp: $630kMr. Motti Farbstein (Age 60)CEO and Chief Financial & Operating Officer Comp: $423kDr. Sari Fishman Ph.D. (Age 52)Vice President of Business Development Comp: $340kDr. Ilan Cohn Ph.D. (Age 70)Co-Founder & Director Dr. Stephen A. Harrison FACPM.D., Member of Clinical Advisory Board & Consulting Chief Medical OfficerKey CompetitorsBioRestorative TherapiesNASDAQ:BRTXNavidea BiopharmaceuticalsNYSE:NAVBPHAXIAM TherapeuticsNASDAQ:PHXMEiger BioPharmaceuticalsNASDAQ:EIGRGalectoNASDAQ:GLTOView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 154,363 shares on 2/13/2024Ownership: 4.361%View All Institutional Transactions CANF Stock Analysis - Frequently Asked Questions Should I buy or sell Can-Fite BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CANF shares. View CANF analyst ratings or view top-rated stocks. What is Can-Fite BioPharma's stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for Can-Fite BioPharma's stock. Their CANF share price targets range from $12.00 to $18.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 638.9% from the stock's current price. View analysts price targets for CANF or view top-rated stocks among Wall Street analysts. How have CANF shares performed in 2024? Can-Fite BioPharma's stock was trading at $2.20 at the start of the year. Since then, CANF stock has decreased by 7.7% and is now trading at $2.03. View the best growth stocks for 2024 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.04. The business earned $0.16 million during the quarter, compared to analysts' expectations of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 113.75% and a negative net margin of 1,027.46%. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma's stock reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CANF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
